Acute myeloid leukemia in children
Authors:
L. Šrámková
Authors place of work:
Klinika dětské hematologie a onkologie 2. LF UK a FN Motol, Praha, přednosta prof. MUDr. J. Starý, DrSc.
Published in the journal:
Čes-slov Pediat 2015; 70 (2): 108-113.
Category:
Acute leukemias in children
Summary
Acute myeloid leukemia (AML) in children constitute only 15% of all leukemias and is therefore considerably less frequent than acute lymphoblastic leukemia (ALL). The diagnosis in suspected haematological malignancy is based on bone marrow aspiration in a specialized centers with morphology, cytometry, cytogenetic and molecular genetic examination, which distinguishes AML from the more common ALL and can divide the subtypes of AML. In recent years the importance of molecular genetic analysis increases with the aim of finding targeted therapies for individual subtypes of AML. Treatment is based on the short cycle high-dose chemotherapy, thus can be achieved complete remission in 90% of patients, children with high risk of relapse are later indicated for allogeneic bone marrow transplantation in first remission. Supportive therapy is an important pillar of comprehensive care for patients with AML due to the risk of fatal complications most infectious or bleeding. Despite the very intensive treatment, approximately 30% of children will experience relapse, the treatment of relapse has not reached satisfactory results.
Patients after successful treatment of AML require long term follow up focused on cardiological controls due to the risk of cardiomyopathy after treatment with anthracyclines. Chance to be cured for AML patient in the last 20 years has increased significantly, currently reaches 65–70%, mainly thanks to advances in supportive therapy and bone marrow transplantation.
Key words:
acute myeloid leukemia, children, chemotherapy, bone marrow transplantation
Zdroje
1. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French--American-British Cooperative Group. Ann Intern Med 1985; 103: 620–625.
2. Neuhoff Ch, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 2010; 28: 2682–2689.
3. van der Velden VH, van der Sluijs-Geling A, Gibson BE, et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol. Leukemia 2010; 24: 1599–1606.
4. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010; 11: 543–552.
5. Creutzig U, Zimmermann M, Ritter J, et al. Definition of a standard-risk group in children with AML. Br J Haematol 1999; 104: 630–639.
6. Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensifica-tion with high-dose cytarabine and mitoxantrone: Results of study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol 2001; 19: 2705–2713.
7. Creutzig U, Ritter J, Zimmermann M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: Results of study AML-BFM 93. Leukemia 2001; 15: 348–354.
8. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361 (13): 1249–1259.
9. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012; 120 (16): 3187–3205.
10. Stary J, Gajdos P, Blazek B, et al. Sjednocení léčby dětí s akutní mye-loidní leukémií v České republice podle protokolu AML-BFM 93. Cas Lek ces 2004; 143: 257–263.
11. Stary J, Vavra V, Gajdos P, et al. Druhá celostátní léčebná studie AML--BFM 98 zvýšila úspěšnost v dosažení remise a zlepšila celkové přežití dětí s akutní myeloidní leukémií v České republice. Trans Hemat dnes 2008; 14: 166–174.
12. Sramkova L, Sterba J, Stary J, et al. Development of treatment and clinical results in childhood acute myeloid leukemia in the Czech Republic. Memo February 2013; 6 (1): 41–45.
13. Lehrnbecher T, Sung L. Anti-infective prophylaxis in pediatric patients with acute myeloid leukemia. Expert Rev Hematol 2014 Dec; 7 (6): 819–830.
14. Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia: Analysis of the prospective multiinstitutional clinical trial AML-BFM 93. Leukemia 2004; 18: 72–77.
15. Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute mye-loid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004; 22: 4384–4393.
16. Barlogis V, Auquier P, Bertrand Y, et al. Late cardiomyopathy in childhood acute myeloid leukemia survivors: an L.E.A. study. Haematologica 2015; Jan 23 [Epub ahead of print].
17. Kremer LC, van der Pal HJ, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002; 13 (6): 819–829.
18. Lipshultz SE, Adams MJ, Colan SD, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 2013; 128 (17): 1927–1995.
19. Shankar SM, Marina N, Hudson MM, et al. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children‘s Oncology Group. Pediatrics 2008; 121 (2): e387–e396.
20. Berbis J, Michael G, Baruchel A, et al. Cohort profile: The French Childhood Cancer Survivor Study for Leukaemia (LEA Cohort). Int J Epidemiol 2014: 1–9.
21. Zdrahalova K, Sedlacek P, Smisek P, et al. Léčebná studie Relapsed AML 2001/01, 02 pro děti s relapsem akutní myeloidní leukemie nebo primárně rezistentní nemocí zlepšila jejich naději na vyléčení. Trans Hemat dnes 2011; 17: 113–121.
22. Locatelli F, Masetti R, Rondelli R, Zecca M, et al Outcome of children with high-risk acute myeloid leukemia given autologous or allogeneic hematopoietic cell transplantation in the aieop AML-2002/01 study. Bone Marrow Transplant 2014; Nov 10.
Štítky
Neonatology Paediatrics General practitioner for children and adolescentsČlánok vyšiel v časopise
Czech-Slovak Pediatrics
2015 Číslo 2
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Najčítanejšie v tomto čísle
- Acute myeloid leukemia in children
- Acute lymphoblastic leukemia
- Leukemias in children in the 21st century
- Immunophenotyping and other applications of flow cytometry in acute leukemias